List of Excipients in Branded Drug NULIBRY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Sentynl Therapeutics Inc	NULIBRY	fosdenopterin hydrobromide	42358-295	ASCORBIC ACID	2028-02-26
Sentynl Therapeutics Inc	NULIBRY	fosdenopterin hydrobromide	42358-295	HYDROCHLORIC ACID	2028-02-26
Sentynl Therapeutics Inc	NULIBRY	fosdenopterin hydrobromide	42358-295	MANNITOL	2028-02-26
Sentynl Therapeutics Inc	NULIBRY	fosdenopterin hydrobromide	42358-295	SODIUM HYDROXIDE	2028-02-26

NULIBRY Excipient Strategy and Commercial Opportunities in Fosdenopterin

Last updated: September 3, 2026

NULIBRY is a high-value, low-volume sterile injectable for molybdenum cofactor deficiency type A, a fatal ultra-rare metabolic disease. Its excipient strategy is deliberately narrow: the product is a lyophilized fosdenopterin sodium formulation containing mannitol, with reconstitution and dilution before intravenous infusion. The commercial opportunity is strongest in pediatric sterile manufacturing, low-bioburden fill-finish, cold-chain logistics, ready-to-use dosing systems, and lifecycle extensions rather than in commodity excipient substitution.

What is NULIBRY and how is it administered?

NULIBRY is the brand name for fosdenopterin, a cyclic pyranopterin monophosphate replacement therapy. The FDA approved NULIBRY in February 2021 for patients with molybdenum cofactor deficiency type A, including use in newborns, infants, children, and adults [1].

The product is administered by intravenous infusion after reconstitution and dilution. The commercial dosage is weight-based and varies by age and treatment day. The product is supplied as a sterile, single-dose lyophilized powder in a vial [2].

Attribute	NULIBRY profile
Active ingredient	Fosdenopterin sodium
Therapeutic area	Molybdenum cofactor deficiency type A
Dosage form	Sterile lyophilized powder for solution
Route	Intravenous infusion
Population	Neonates, infants, children, and adults
Vial format	Single-dose vial
Key listed excipient	Mannitol
Sponsor and manufacturer context	Originally developed by Origin Biosciences; Origin was acquired by Alexion, AstraZeneca Rare Disease
FDA approval	February 26, 2021
Regulatory pathway	Orphan drug and accelerated approval framework
Initial U.S. orphan exclusivity endpoint	February 2028, subject to regulatory and market-status conditions

NULIBRY does not compete with a conventional small-molecule generic. The relevant commercial risks are manufacturing complexity, specialized distribution, clinical adoption, and potential future therapies for molybdenum cofactor deficiency.

What excipients are used in NULIBRY?

The NULIBRY prescribing information identifies mannitol as an inactive ingredient in the lyophilized formulation [2]. The active pharmaceutical ingredient is fosdenopterin sodium.

Mannitol has several formulation functions in sterile lyophilized products:

• It can provide a crystalline bulking matrix.
• It can improve cake structure after freeze-drying.
• It can support consistent vial appearance and reconstitution.
• It can help control the physical properties of the dried product.
• It is widely available in parenteral pharmaceutical grades.

The limited excipient composition reduces formulation complexity and may reduce risks associated with preservative toxicity, surfactant interactions, or excipient-related pediatric tolerability. The tradeoff is that the formulation has fewer levers available to manage instability, aggregation, adsorption, or reconstitution performance.

Why mannitol is commercially relevant

Mannitol is a well-established excipient for injectable lyophilized products. Its use creates a relatively accessible supply market compared with specialized amino acids, synthetic polymers, or novel stabilizers. The commercial value is therefore unlikely to come from supplying mannitol alone.

Higher-value opportunities exist in:

1. Pharmaceutical-grade mannitol with tight control of endotoxin, bioburden, and particulate burden.
2. Low-moisture grades optimized for lyophilization.
3. Excipient lots with reduced variability in crystallinity and particle size.
4. Dual-source qualification packages for rare-disease products.
5. Analytical support for extractables, leachables, and container-closure compatibility.

The product’s low annual volume means that the manufacturer is likely to prioritize supply reliability, quality history, and regulatory continuity over modest price reductions.

What formulation attributes create the main excipient risks?

The principal formulation risks arise from the interaction between fosdenopterin sodium, mannitol, residual moisture, the vial closure, and the infusion process.

Chemical stability

Fosdenopterin is a phosphorylated pterin derivative. Phosphate-containing compounds can be sensitive to hydrolysis, pH, ionic strength, and metal-ion exposure. The commercial formulation must control:

• Water activity after lyophilization.
• Reconstitution pH.
• Oxygen exposure.
• Trace metal contamination.
• Light exposure where relevant.
• Hold time after reconstitution and dilution.

The excipient strategy should therefore focus on low residual moisture and tight control of the reconstituted solution rather than on adding multiple stabilizers without a demonstrated benefit.

Physical stability

Mannitol can crystallize during freezing and drying. Controlled crystallization can provide a strong cake, but uncontrolled phase behavior can change reconstitution time, residual moisture, and product uniformity. Development work should evaluate:

• Mannitol polymorphic form.
• Freeze-concentration effects.
• Collapse temperature and product temperature.
• Cake shrinkage or melt-back.
• Reconstitution time.
• Visible and subvisible particles.
• Vial-to-vial dose recovery.

A supplier capable of controlling mannitol polymorphism and particle attributes has greater strategic value than a low-cost commodity supplier.

Container-closure interaction

NULIBRY is a low-dose, high-value injectable. Adsorption to glass, elastomeric closures, tubing, or infusion components can create disproportionate product loss. Compatibility studies should cover:

• Type I glass vials.
• Bromobutyl or chlorobutyl stoppers.
• Aluminum seals.
• Syringes and transfer devices.
• Polyvinyl chloride and polyolefin infusion bags.
• Administration tubing.
• Contact time during reconstitution and infusion.

The final formulation and administration system should be assessed together. A nominally stable vial formulation can still produce dose loss if the diluted solution interacts with the delivery materials.

How does the NULIBRY excipient strategy compare with competing rare-disease injectables?

NULIBRY has a simpler excipient profile than many biologic or peptide injectables. It does not require a surfactant system comparable to polysorbate-containing antibodies, nor does it require a complex buffer platform comparable to many protein products.

Product characteristic	NULIBRY	Typical monoclonal antibody	Typical enzyme-replacement therapy
Active ingredient	Small phosphorylated molecule	Protein	Protein or enzyme
Dosage form	Lyophilized sterile powder	Liquid or lyophilized	Liquid or lyophilized
Common excipient burden	Low	Moderate	Moderate to high
Surfactant requirement	Not identified in U.S. label	Often present	Product-dependent
Primary stability issue	Moisture, pH, hydrolysis, adsorption	Aggregation and particulates	Aggregation, oxidation, activity loss
Pediatric administration	Weight-based IV infusion	Often infusion-based	Often infusion-based
Generic substitution risk	Low in near term	Biosimilar pathway	Biosimilar or follow-on biologic pathway

NULIBRY’s simplicity can reduce development and manufacturing complexity. It does not eliminate technical risk because the active ingredient is administered to a vulnerable pediatric population at low patient numbers and high clinical consequence.

What commercial opportunities exist for NULIBRY excipient suppliers?

The most attractive opportunities are specialized services linked to product quality rather than bulk excipient sales.

Pharmaceutical-grade mannitol

Mannitol suppliers can compete on:

• Compendial compliance.
• Sterile or low-endotoxin manufacturing capability.
• Batch-to-batch consistency.
• Supply continuity.
• Change-control discipline.
• Documentation suitable for a biologics or sterile-drug master file.
• Low particulate and low bioburden performance.

A supplier that becomes part of the approved NULIBRY supply chain may be difficult to replace because even a non-active ingredient change can trigger comparability, stability, and regulatory work.

Lyophilization development

Contract development and manufacturing organizations can offer:

• Cycle development.
• Scale-up from laboratory to commercial freeze-dryers.
• Thermal analysis.
• Residual-moisture optimization.
• Vial loading and stoppering studies.
• Reconstitution testing.
• Stability modeling.

NULIBRY’s ultra-rare indication makes efficient campaign production important. A CDMO that can run small, validated sterile batches has a stronger fit than a high-volume facility optimized for blockbuster products.

Pediatric delivery systems

Potential opportunities include:

• Low-dead-volume transfer devices.
• Premeasured reconstitution systems.
• Closed-system vial adapters.
• Syringe-based dosing aids.
• Infusion-bag preparation systems.
• Home-infusion support materials, where clinically and operationally appropriate.

The opportunity is constrained by the need to preserve the approved route, dose accuracy, sterility assurance, and compatibility profile. Any new device would require human-factors, extractables, leachables, and regulatory assessment.

Alternative dosage forms

An oral, subcutaneous, or ready-to-use intravenous formulation could materially expand commercial value by reducing infusion burden. The development barriers are substantial:

• Fosdenopterin must reach the relevant systemic compartment.
• Oral delivery would face permeability and chemical-stability challenges.
• Pediatric dosing must remain accurate across a wide weight range.
• A liquid formulation could increase hydrolysis or microbial-control requirements.
• A concentrated formulation could increase local tolerability and compatibility risks.

The strongest near-term formulation opportunity is likely a ready-to-reconstitute or ready-to-dilute injectable presentation rather than an entirely new route.

What FDA regulatory status affects excipient commercialization?

NULIBRY received FDA accelerated approval based on a surrogate endpoint, urinary sulfite levels, that is reasonably likely to predict clinical benefit [1]. The product also received orphan-drug designation and other expedited-development benefits.

For excipient and packaging vendors, the regulatory implications are significant:

• The approved formulation is part of the product’s chemistry, manufacturing, and controls package.
• Excipient changes require formal comparability assessment.
• Changes affecting stability, reconstitution, particulate levels, or dose recovery may require prior FDA review.
• New excipients or materially different grades would require additional toxicology and quality justification.
• A manufacturing-site or supplier change must be managed through documented change control.

FDA’s inactive-ingredient database can support initial precedent analysis, but it does not establish that a different grade or concentration is interchangeable in NULIBRY [3].

When does NULIBRY lose exclusivity and what is the generic risk?

NULIBRY’s seven-year orphan-drug exclusivity began with its February 2021 approval and is expected to run into February 2028, assuming no statutory extension or other change [1]. Orphan exclusivity prevents FDA approval of the same drug for the same disease or condition during the exclusivity period, subject to statutory exceptions.

Patent protection and regulatory exclusivity are separate. A generic applicant could face:

• Formulation patents.
• Manufacturing-process patents.
• Use patents.
• Composition-of-matter patents.
• Pediatric dosing claims.
• Patent listings in the Orange Book, if applicable.
• Patent litigation under the Hatch-Waxman framework.

NULIBRY is a small-molecule drug, so an abbreviated new drug application pathway is theoretically possible. Practical development would still require demonstration of pharmaceutical equivalence and bioequivalence or another FDA-accepted route. The intravenous route can make bioequivalence more straightforward than for orally absorbed products, but formulation composition, reconstitution, concentration, and administration conditions remain important.

No biosimilar pathway applies to fosdenopterin. Biosimilar risk is therefore not the relevant competitive framework. The relevant risk is generic or follow-on injectable competition, together with new disease-modifying therapies.

What Orange Book and Paragraph IV issues affect NULIBRY?

The Orange Book status of NULIBRY must be assessed through current FDA listing data because patent listings and regulatory exclusivity can change over time [4]. A Paragraph IV certification would assert that an Orange Book-listed patent is invalid, unenforceable, or not infringed.

The commercial consequences would depend on:

• The number and scope of listed patents.
• Whether the claims cover fosdenopterin itself or only formulation and use.
• Patent expiration dates.
• The first applicant’s eligibility for 180-day exclusivity.
• Whether the reference product has pediatric exclusivity.
• The timing of litigation and FDA approval.

A narrow excipient claim generally provides weaker exclusionary coverage than a composition-of-matter claim. A formulation patent can still delay competition if it covers the only commercially practical lyophilized presentation and survives validity and infringement challenges.

How strong is the NULIBRY patent estate?

The strongest possible estate would combine composition-of-matter claims, crystalline or salt-form claims, sterile lyophilized formulation claims, treatment claims, and manufacturing claims. The practical strength of each category differs.

Patent category	Strategic value	Generic vulnerability
Fosdenopterin composition claims	Highest	Depends on remaining term and claim validity
Sodium-salt or solid-form claims	High	Can be designed around if alternative forms are viable
Lyophilized formulation claims	Moderate to high	Vulnerable if alternative excipients or cycles work
Method-of-use claims	Moderate	Depends on enforceability and approved labeling
Manufacturing claims	Variable	Can be avoided through alternate processes
Device or administration claims	Moderate	Often avoidable through alternative components

Mannitol itself is unlikely to provide meaningful exclusivity because it is a widely used excipient. The defensible IP value is more likely to arise from the combination of fosdenopterin sodium, specific ratios, moisture limits, reconstitution performance, and treatment use.

What generic launch scenarios exist for NULIBRY?

Three scenarios are commercially plausible after regulatory exclusivity and enforceable patent barriers expire.

Scenario 1: No near-term generic launch

A generic developer may avoid the market because the patient population is extremely small, clinical distribution is specialized, and sterile injectable manufacturing costs are high. This outcome would preserve substantial pricing power.

Scenario 2: One specialized injectable competitor

A single generic or specialty manufacturer could enter with a closely comparable lyophilized vial. The entrant would likely compete on payer contracting, hospital procurement, and supply reliability rather than broad retail distribution.

Scenario 3: Formulation-led competition

A competitor could develop a more convenient presentation, such as a ready-to-use solution or improved reconstitution format. This would require a separate regulatory and clinical strategy but could create competitive pressure even without direct generic substitution.

What licensing and partnership opportunities exist?

NULIBRY-related commercial opportunities are concentrated in partnerships involving:

• Sterile fill-finish capacity.
• Lyophilization technology.
• Pediatric drug-delivery devices.
• Regional distribution.
• Genetic diagnosis and newborn-screening networks.
• Manufacturing rights in territories where rare-disease access is limited.
• Formulation improvement and lifecycle management.

The most valuable partnership assets are validated manufacturing processes, regulatory documentation, and access to diagnosed patients. A raw-material supplier with no regulatory history in sterile drug products has limited leverage compared with a supplier already qualified for pharmaceutical production.

Key Takeaways

• NULIBRY is a lyophilized intravenous fosdenopterin sodium product for molybdenum cofactor deficiency type A.
• Mannitol is the principal listed inactive ingredient in the U.S. formulation.
• The excipient opportunity is concentrated in pharmaceutical-grade supply, lyophilization, sterile fill-finish, packaging compatibility, and pediatric delivery systems.
• Mannitol is unlikely to create meaningful standalone exclusivity.
• The strongest formulation IP would cover the active ingredient-excipient combination, moisture limits, reconstitution performance, and manufacturing process.
• NULIBRY received FDA approval in February 2021 and carries seven-year orphan-drug exclusivity expected to extend into February 2028.
• Biosimilar competition is not applicable. Generic injectable and next-generation formulation competition are the relevant risks.
• Commercial entry is constrained by the small patient population, specialized distribution, sterile manufacturing requirements, and high regulatory switching costs.

FAQs

Can mannitol be replaced in a NULIBRY-like formulation?

Potentially, but replacement would require formulation, stability, reconstitution, particulate, sterility, and regulatory comparability studies. A replacement excipient could affect the lyophilized cake, residual moisture, dose recovery, and storage stability.

Is NULIBRY a biologic eligible for biosimilar competition?

No. Fosdenopterin is a small-molecule active ingredient. Competitive entry would generally follow generic-drug or new-drug pathways rather than the biosimilar pathway.

Is NULIBRY suitable for a prefilled syringe?

The product is supplied as a lyophilized vial and requires reconstitution and dilution before infusion. A prefilled or ready-to-use presentation would require new compatibility, stability, sterility, dose-delivery, and regulatory studies.

What is the most valuable NULIBRY manufacturing capability?

Validated sterile lyophilization and small-batch fill-finish capacity is likely more valuable than commodity excipient supply. The capability must support low-volume production, pediatric dose flexibility, and strong quality documentation.

Can an excipient supplier obtain patent protection around a NULIBRY formulation?

An excipient supplier could seek patents on a new formulation, specific concentration range, lyophilization cycle, reconstitution system, or delivery device. Patent value would depend on novelty, non-obviousness, enablement, and whether the resulting claims can block commercially viable alternatives.

References

1. U.S. Food and Drug Administration. (2021). FDA approves first treatment for molybdenum cofactor deficiency type A. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-molybdenum-cofactor-deficiency-type

2. U.S. Food and Drug Administration. (2024). NULIBRY (fosdenopterin) prescribing information. FDA.

3. U.S. Food and Drug Administration. (2024). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book